Reviewing Protalix BioTherapeutics (PLX) & Its Peers

Protalix BioTherapeutics (NYSE:PLX – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Protalix BioTherapeutics to related companies based on the strength of its analyst recommendations, risk, institutional ownership, valuation, earnings, dividends and profitability.

Valuation and Earnings

This table compares Protalix BioTherapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Protalix BioTherapeutics $84.69 million $8.31 million 12.20
Protalix BioTherapeutics Competitors $730.93 million $10.70 million -18.81

Protalix BioTherapeutics’ rivals have higher revenue and earnings than Protalix BioTherapeutics. Protalix BioTherapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Protalix BioTherapeutics has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics’ rivals have a beta of -1.88, indicating that their average share price is 288% less volatile than the S&P 500.

Insider and Institutional Ownership

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Protalix BioTherapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Protalix BioTherapeutics -21.03% -30.89% -11.74%
Protalix BioTherapeutics Competitors -12,319.70% -407.93% -30.95%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Protalix BioTherapeutics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protalix BioTherapeutics 0 0 1 0 3.00
Protalix BioTherapeutics Competitors 9916 15312 45656 1602 2.54

Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 293.44%. As a group, “Biotechnology” companies have a potential upside of 126.22%. Given Protalix BioTherapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Protalix BioTherapeutics is more favorable than its rivals.

Summary

Protalix BioTherapeutics beats its rivals on 7 of the 13 factors compared.

Protalix BioTherapeutics Company Profile

(Get Free Report)

Protalix BioTherapeutics is an Israel-based biopharmaceutical company that develops and manufactures recombinant therapeutic proteins using its proprietary plant-cell expression system, ProCellEx. The company focuses on treatments for rare and chronic diseases and was founded in 1993. Its products include Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease, and Elfabrio (pegunigalsidase alfa), an enzyme replacement therapy for Fabry disease. Protalix developed Elfabrio in collaboration with Chiesi Global Rare Diseases; commercialization and distribution are handled through partner arrangements in multiple markets.

Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.